Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: J Allergy Clin Immunol. 2014 Oct 19;135(2):425–440. doi: 10.1016/j.jaci.2014.09.005

Figure 2. DNA-PK is involved in allergic lung inflammation, and its inhibition reduces eosinophilia, mucus hypersecretion, AHR, and IgE production in a mouse model of asthma.

Figure 2

(A) Lung tissue sections from an asthmatic and a non-asthmatic individual were subjected to IHC staining with antibodies to human VCAM-1. WT mice were subjected to OVA sensitization followed by challenge or left untreated. Mice were administered i.p. 5 mg/kg NU7441 or saline thirty minutes after OVA challenge. Control mice received either 5 mg/kg of NU7441 or saline. Mice were sacrificed 48 h later. (B) H&E stain of lung sections. (C) Assessment of differentially stained cells in BALF. Data are expressed as total number of cells per mouse. Data are means ± SD of values from at least six mice per group. *, difference from unchallenged mice; #, difference from OVA-challenged mice; p < 0.01. (D) PAS staining of lung sections. (E) Assessment of Penh recorded 24 h after a single OVA challenge using whole body plethysmography upon exposure to the indicated concentrations of aerosolized methacholine (MeCh). Results are plotted as maximal fold increase of Penh relative to baseline and expressed as mean ± SEM where n=6 mice per group. *, difference from control mice; #, difference from OVA-challenged mice, p < 0.01. Assessment of sera (F) or BALF (G) collected from the different experimental groups for OVA-specific IgE. *, difference from control mice; #, difference from OVA-challenged mice; ¶, difference from OVA-sensitized but not challenged (OVA(S)) mice, p < 0.01. (H) IHC staining of lung sections with antibodies to mouse VCAM-1. Bars: 5 μm. (I) Assessment of Penh after multiple OVA challenges (M) and a single NU7441 administration thirty minutes after the last challenge; measurements were conducted 24 h after the last OVA challenge. Results are plotted and analyzed as in (E). (J) Assessment of OVA-specific IgE in sera or BALF collected from the experimental groups described in (I). *, difference from control mice, p < 0.01; #, difference from OVA-challenged mice; ¶, difference from OVA-sensitized but not challenged mice (OVA(S)), p < 0.01.